Galectin-3 is a member of the galectin family, which are β‑galactoside‑binding lectins with≥
1 evolutionary conserved carbohydrate‑recognition domain. It binds proteins in a …

Results from the DANISH Study (Danish Study to Assess the Efficacy of ICDs in Patients
With Non-Ischemic Systolic Heat Failure on Mortality) suggest that for many patients with …

Heart failure is a leading cause of mortality and hospitalization worldwide. Cardiac fibrosis,
resulting from the excessive deposition of collagen fibers, is a common feature across the …

This article provides an update regarding the most recent published literature on galectin-3
as a biomarker in heart failure (HF) and gives an outlook toward its use as a biotarget. 1 In …

Cerebrovascular diseases such as ischemic stroke, brain hemorrhage, and subarachnoid
hemorrhage provoke cardiac complications such as heart failure, neurogenic stress-related …

Cardiac fibrosis is associated with non-ischemic dilated cardiomyopathy, increasing its
morbidity and mortality. Cardiac fibroblast is the keystone of fibrogenesis, being activated by …

Galectin-3 plays a prominent role in chronic inflammation and has been implicated in the
development of many disease conditions, including heart disease. Galectin-3, a regulatory …

Summary Galectin‐3, a β‐galactoside‐binding lectin, is a new important player in the
progression of heart failure (HF) and is also linked to poor outcome in patients with …

Galectin-3 is an emerging biomarker of myocardial fibrosis, inflammation, and immune
response. We sought to examine the relation of plasma galectin-3 with cardiovascular (CVD) …

Myocardial fibrosis is observed in various cardiovascular diseases and plays a key role in
the impairment of cardiac function. Endomyocardial biopsy, as the gold standard for the …